Retatrutide: The Biggest Phase 2 Numbers On This Desk, and Zero Approvals

The short version

Retatrutide — also called LY3437943 — is a single molecule that activates three separate hormone receptors at once: GIP, GLP-1, and glucagon. It is being developed by Eli Lilly and is currently in Phase 3 trials (the TRIUMPH program). It has not been approved by the FDA or any other regulator anywhere, as of mid-2026. Every efficacy and safety number on this page comes from Phase 1 and Phase 2 studies — Phase 3 results are not published yet.

In a 48-week Phase 2 obesity trial, the 12 mg dose produced a mean 24.2% body-weight reduction versus 2.1% for placebo — the largest Phase 2 weight-loss figure reported for any incretin-class compound so far ^[14]. In a Phase 2 trial for type 2 diabetes, 12 mg lowered HbA1c by 2.02 percentage points at 24 weeks ^[15]. This page states plainly, throughout, that these are Phase 2 numbers, not an approved product's label.

What it is

Retatrutide is a 39-amino-acid synthetic peptide built on a GIP-hormone backbone, with a fatty-acid side chain attached to extend its half-life enough for once-weekly dosing — the same general engineering trick used across this class of drugs. Its molecular formula is C221H342N46O68.

Cryo-EM structures published in 2024 resolved exactly how it binds all three of its target receptors — GLP-1R, GIPR, and GCGR — at atomic resolution, and found it is not a balanced triple agonist: it is roughly 8.9 times more potent at the GIP receptor than the natural hormone, but only 0.3 and 0.4 times as potent at the glucagon and GLP-1 receptors respectively ^[12]. That is a molecule engineered to lean harder on one receptor than the other two, not to hit all three evenly.

How it works

Retatrutide inherits the appetite-suppressing, insulin-boosting pharmacology of GLP-1 and GIP receptor activation, and adds a third piece: controlled activation of the glucagon receptor. Glucagon normally tells the liver to release stored sugar — the opposite of what a diabetes drug wants — but in combination with strong insulin-boosting signals from the other two receptors, mild glucagon activation instead appears to raise energy expenditure through brown-fat thermogenesis and fat burning, without meaningfully raising blood sugar.

The practical upshot researchers describe: the GLP-1/GIP side reduces food intake, and the glucagon side increases how much energy the body burns — working both sides of the weight-loss equation at once, rather than just one ^[11]. That is the mechanistic argument for why retatrutide's Phase 2 weight-loss numbers run ahead of dual-agonist and single-agonist compounds studied so far.

What the research shows

Structural basis for triple agonism. A 2024 cryo-EM study resolved retatrutide bound to all three of its target receptor complexes, confirming the triple-agonist mechanism directly rather than inferring it from downstream effects ^[12].

Phase 2 obesity trial. In 338 adults with obesity over 48 weeks, the 12 mg dose produced a mean 24.2% body-weight reduction versus 2.1% with placebo. Gastrointestinal side effects were dose-related and mostly mild to moderate; a dose-dependent heart-rate increase peaked around 24 weeks ^[14].

Phase 2 type 2 diabetes trial. In 281 adults with type 2 diabetes over 36 weeks, 12 mg lowered HbA1c by 2.02 percentage points and body weight by 16.94%, versus placebo. No severe hypoglycemia or deaths were reported; GI side effects occurred in 35% of participants ^[15].

Fatty liver substudy. In 98 adults with obesity and metabolic-associated fatty liver disease, 12 mg reduced liver fat by 82.4% at 24 weeks, and 86% of participants reached normal liver-fat levels — sustained out to 48 weeks ^[13].

Synthesis. A 2025 narrative review characterizes the Phase 1/2 weight-loss data as a genuine step-change versus earlier incretin drugs, while flagging GI tolerability and the dose-dependent heart-rate signal as the open questions Phase 3 needs to settle ^[11].

What is missing from all of it: long-term outcomes data and regulatory approval. Neither exists yet.

Reported effects, cautions & safety

Research-use communities describe a profile broadly similar to other incretin-class compounds, with one addition attributed to the glucagon-receptor piece. These accounts are anecdotal, not clinical evidence — drawn from online communities and peptide-industry blogs, not controlled studies, and none of them include a verified dose.

Reported benefits: a near-total quieting of food-related thoughts, described as more complete than with other incretin-class compounds; rapid, pronounced weight loss; and a distinct sensation of warmth or mild thermogenic feeling that community discussion attributes to the glucagon-receptor arm.

Reported downsides: nausea peaking several hours after injection, especially in the early weeks; a noticeably elevated resting heart rate that some track on wearables; sulfur burps, constipation, and early fatigue; and a smaller group reporting sleep disturbances.

What the clinical record actually flags: retatrutide is unapproved and available outside clinical trials only through a gray market with no verified purity, sterility, or identity — the FDA issued more than 50 warning letters to vendors in 2025 ^[11][14]. Nausea affected up to 45% of participants at the highest Phase 2 dose and drove an 18% discontinuation rate at that level ^[14]. The dose-dependent heart-rate increase seen in Phase 2 is real, and its long-term cardiovascular meaning is still being studied in an ongoing dedicated trial ^[14]. Combining it with insulin or sulfonylurea medication raises hypoglycemia risk that requires monitoring ^[15].

Where it fits in Research Peptide Fundamentals

Retatrutide is the frontier compound on this desk, and the least settled. Where semaglutide has close to two decades of trial infrastructure and multiple approved indications, retatrutide has two pivotal Phase 2 trials, a liver-disease substudy, and no Phase 3 data yet. It sits in the same broad incretin-receptor family as semaglutide but takes the mechanism one step further — a third receptor, a bigger reported effect, and a correspondingly bigger gap in what is actually confirmed. Reading the two side by side is the clearest way to see what "more receptors" has and has not bought so far. See the full comparison.